Clinical Outcomes, Drug Toxicity, and Emergence of Ceftazidime-Avibactam Resistance Among Patients Treated for Carbapenem-Resistant Enterobacteriaceae Infections

Clin Infect Dis. 2016 Dec 15;63(12):1615-1618. doi: 10.1093/cid/ciw636. Epub 2016 Sep 13.

Abstract

Thirty-seven carbapenem-resistant Enterobacteriaceae (CRE)-infected patients were treated with ceftazidime-avibactam. Clinical success and survival rates at 30 days were 59% (22/37) and 76% (28/37), respectively. In 23% (5/22) of clinical successes, CRE infections recurred within 90 days. Microbiologic failure rate was 27% (10/37). Ceftazidime-avibactam resistance was detected in 30% (3/10) of microbiologic failures.

Keywords: Klebsiella pneumoniae carbapenemase; carbapenem-resistant Enterobacteriaceae; ceftazidime-avibactam resistance.

MeSH terms

  • Adult
  • Aged
  • Azabicyclo Compounds / adverse effects
  • Azabicyclo Compounds / therapeutic use*
  • Carbapenem-Resistant Enterobacteriaceae*
  • Ceftazidime / adverse effects
  • Ceftazidime / therapeutic use*
  • Drug Combinations
  • Drug Resistance, Bacterial
  • Enterobacteriaceae Infections / drug therapy*
  • Female
  • Humans
  • Male
  • Middle Aged
  • Retrospective Studies
  • Treatment Outcome
  • beta-Lactamase Inhibitors / adverse effects
  • beta-Lactamase Inhibitors / therapeutic use*

Substances

  • Azabicyclo Compounds
  • Drug Combinations
  • avibactam, ceftazidime drug combination
  • beta-Lactamase Inhibitors
  • Ceftazidime